Tablets Medopharm Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 9.42 Cr
as on 15-11-2024
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 Cr
as on 15-11-2024
- Revenue 273.63%
(FY 2023)
- Profit 57.19%
(FY 2023)
- Ebitda 45.47%
(FY 2023)
- Net Worth -55.00%
(FY 2023)
- Total Assets 117.96%
(FY 2023)
About Tablets Medopharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.42 Cr.
The company currently has active open charges totaling ₹4.50 Cr.
Siddhartha Daga, Hastimal Chordia, Balamurugan Rengasamy, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909TN2019PTC130558
- Company No.
130558
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2019
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Tablets Medopharm?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Siddhartha Daga  | Director | 01-Nov-2019 | Current |
| Hastimal Chordia | Director | 02-Apr-2024 | Current |
| Balamurugan Rengasamy | Director | 01-Nov-2019 | Current |
| Tushar Chordia | Whole-Time Director | 01-Nov-2019 | Current |
Financial Performance and Corporate Structure Insights of Tablets Medopharm.
Tablets Medopharm Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 273.63% increase. The company also saw a substantial improvement in profitability, with a 57.19% increase in profit. The company's net worth observed a substantial decline by a decrease of 55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tablets Medopharm?
In 2023, Tablets Medopharm had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 22 Aug 2023 | ₹4.50 Cr | Open |
How Many Employees Work at Tablets Medopharm?
Tablets Medopharm has a workforce of 13 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tablets Medopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tablets Medopharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
